Advancements in research on lactate dehydrogenase A in urinary system tumors.
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
30 Aug 2024
30 Aug 2024
Historique:
received:
12
06
2024
accepted:
22
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
30
8
2024
Statut:
epublish
Résumé
Tumors of the urinary system, such as prostate cancer, bladder cancer, and renal cell carcinoma, are among the most prevalent types of tumors. They often remain asymptomatic in their early stages, with some patients experiencing recurrence or metastasis post-surgery, leading to disease progression. Lactate dehydrogenase A (LDHA) plays a crucial role in the glycolysis pathway and is closely associated with anaerobic glycolysis in urinary system tumors. Therefore, a comprehensive investigation into the intricate mechanism of LDHA in these tumors can establish a theoretical foundation for early diagnosis and advanced treatment. This review consolidates the current research and applications of LDHA in urinary system tumors, with the aim of providing researchers with a distinct perspective.
Identifiants
pubmed: 39215270
doi: 10.1186/s12894-024-01580-y
pii: 10.1186/s12894-024-01580-y
pmc: PMC11363645
doi:
Substances chimiques
L-Lactate Dehydrogenase
EC 1.1.1.27
Isoenzymes
0
Lactate Dehydrogenase 5
EC 1.1.1.27.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
187Informations de copyright
© 2024. The Author(s).
Références
Am J Transl Res. 2019 Nov 15;11(11):6838-6849
pubmed: 31814891
Antioxidants (Basel). 2021 Jun 16;10(6):
pubmed: 34208670
Clin Transl Med. 2022 Mar;12(3):e764
pubmed: 35343073
Transl Androl Urol. 2023 Nov 30;12(11):1645-1657
pubmed: 38106682
Oncotarget. 2016 Nov 8;7(45):74269-74285
pubmed: 27708237
CA Cancer J Clin. 2024 May-Jun;74(3):224-226
pubmed: 38572764
Onco Targets Ther. 2020 Mar 30;13:2613-2627
pubmed: 32280238
Science. 2021 Jan 22;371(6527):405-410
pubmed: 33479154
Eur J Med Res. 2023 Nov 4;28(1):481
pubmed: 37925501
Cell Death Dis. 2024 Jan 17;15(1):64
pubmed: 38233415
Neurology. 1993 Jul;43(7):1414-9
pubmed: 8327147
Proteomics Clin Appl. 2017 Dec;11(11-12):
pubmed: 28975715
Urol Int. 2017;99(2):237-244
pubmed: 27027898
PeerJ. 2023 Aug 1;11:e15749
pubmed: 37547725
Cell Death Dis. 2022 May 7;13(5):443
pubmed: 35525866
Cancer Res. 2022 Mar 01;82(5):831-845
pubmed: 34965937
Tumour Biol. 2015 Sep;36(10):8093-100
pubmed: 25983002
Clin Transl Med. 2021 Jan;11(1):e279
pubmed: 33463054
CA Cancer J Clin. 2024 May-Jun;74(3):229-263
pubmed: 38572751
BMC Cancer. 2018 May 10;18(1):553
pubmed: 29747600
Science. 1964 Aug 7;145(3632):595-7
pubmed: 14163789
J Cancer. 2024 Jan 1;15(3):590-602
pubmed: 38213726
Cancer Res. 2000 Nov 1;60(21):6178-83
pubmed: 11085542
Oncotarget. 2014 Jan 30;5(2):506-18
pubmed: 24504108
Mol Ther Oncolytics. 2020 Jul 21;18:382-395
pubmed: 32913888
Mol Med Rep. 2017 Dec;16(6):8335-8344
pubmed: 28983605
Onco Targets Ther. 2019 Feb 20;12:1423-1432
pubmed: 30863109
Front Oncol. 2019 Nov 29;9:1242
pubmed: 31850191
PeerJ. 2023 Jan 18;11:e14591
pubmed: 36691477
Onco Targets Ther. 2022 Mar 26;15:299-311
pubmed: 35388272
Cancer Sci. 2021 Sep;112(9):3822-3834
pubmed: 34181805
Int J Oncol. 2015 Jul;47(1):287-95
pubmed: 25998032
Oncol Rep. 2019 Jul;42(1):224-230
pubmed: 31180564
Int J Cancer. 2011 May 1;128(9):2085-95
pubmed: 20607826
Oncol Rep. 2019 May;41(5):2844-2854
pubmed: 30864733
Science. 1969 Feb 14;163(3868):701-2
pubmed: 5762937
Eur Urol Focus. 2019 Sep;5(5):831-841
pubmed: 29699892
Genomics Proteomics Bioinformatics. 2023 Feb;21(1):177-189
pubmed: 35278714
Dis Markers. 2022 May 4;2022:9516774
pubmed: 35571619
Mol Carcinog. 2020 Aug;59(8):897-907
pubmed: 32319143
Oncol Lett. 2018 Jul;16(1):866-874
pubmed: 29963157
Oncotarget. 2017 Jun 28;8(40):67663-67669
pubmed: 28978061
Neoplasma. 2022 May;69(3):594-602
pubmed: 35263995
Tumour Biol. 2016 Jun;37(6):8367-74
pubmed: 26733163
Endocr Relat Cancer. 2019 Jan 1;26(1):59-71
pubmed: 30400006
Cancer Res. 2010 Nov 15;70(22):9153-65
pubmed: 20978192
Mol Cancer. 2014 May 05;13:101
pubmed: 24885701
Cancer Res. 1980 Feb;40(2):283-7
pubmed: 7356510
In Vivo. 2017 May-Jun;31(3):415-418
pubmed: 28438871
Theranostics. 2021 Jun 26;11(16):7779-7796
pubmed: 34335964
Theranostics. 2021 Feb 6;11(8):3868-3881
pubmed: 33664867
Cancer Cell Int. 2021 Nov 7;21(1):597
pubmed: 34743698
J Clin Pathol. 2021 Feb;74(2):102-105
pubmed: 32527754
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6658-63
pubmed: 9192621
Anticancer Res. 2016 Apr;36(4):1479-88
pubmed: 27069123
Sci Rep. 2019 Dec 5;9(1):18409
pubmed: 31804603
Carcinogenesis. 2019 Dec 31;40(12):1545-1556
pubmed: 31555797
J Cell Mol Med. 2022 Jul;26(14):3837-3849
pubmed: 35672925
Cancer Res. 1976 Jan;36(1):110-4
pubmed: 1247990
Onco Targets Ther. 2020 Sep 01;13:8771-8782
pubmed: 32943883
Cancer Cell. 2006 Jun;9(6):425-34
pubmed: 16766262